Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TPST 12.06.2024
About Gravity Analytica
Recent News
- 01.06.2025 - Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
- 12.06.2024 - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
Recent Filings
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 9,450 shares of its common stock under the Company’s 2023 Inducement Plan.
The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
About Tempest TherapeuticsTempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website atwww.tempesttx.com.
Investor & Media Contacts:
Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
1If approved by the FDA
